Fitpod

The FITPOD consortium consisting of Tzu Cancer Therapeutics together with ibidi GmbH and the Universitätsklinikum Düsseldorf has been awarded a Eurostars grant of 1.7M€ from the Rijksdienst voor Ondernemend Nederland (RVO), Bundesministerium für Forschung, Technologie und Raumfahrt and European Union.

Exploiting the established Tzu Circulating Tumor Cell analysis platform, the consortium will develop a deployable device with a dedicated disposable, reagent kit and workflow. This development will support large scale use of the Tzu platform, allowing characterization of actively spreading cells in all metastatic cancer patients.


About the partners

Tzu Cancer Therapeutics:
Tzu Cancer Therapeutics has developed a dedicated platform for the analysis of CTC and utilizes this in-depth view on metastasizing disease for the development of effective therapeutics.
Michiel Stevens, Frank A.W. Coumans PhD, Tom Niessink

Ibidi:
With a large presence in the biological research space, ibidi GmbH is an established manufacturer of (certified) disposables for cell-based assays.
Zeno von Guttenberg, Philipp Linke

University Hospital Dusseldorf:
The Liquid Biopsy Center Düsseldorf at the Universitätsklinikum Düsseldorf is a leading institution in the field of CTC-research and translation, that has pioneered the usage of large blood volumes for highly sensitive CTC analysis
Nikolas Stoecklein, Rui P.L. Neves, Hans Neubauer, Raya Zakiya